Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | PHASE1 | RECRUITING | 63 | — | — | Feb 4, 2026 | Mar 1, 2028 | Jun 4, 2026 | 1 | Australia |
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4298445 (Part A1) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4298445 administered subcutaneously (SC) or intravenously (IV) in healthy participants |
| LY4298445 Placebo (Part A1) | PLACEBO_COMPARATOR | SAD of LY4298445 administered SC or IV in healthy participants |
| LY4298445 (Part A2) | EXPERIMENTAL | SAD of LY4298445 administered SC in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) |
| LY4298445 (Part B) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4298445 administered SC in participants with SLE or RA |
| LY4298445 (Part C) | EXPERIMENTAL | Single dose of LY4298445 administered SC in healthy Japanese and Chinese participants |
| LY4298445 Placebo (Part C) | PLACEBO_COMPARATOR | Single dose of LY4298445 administered SC in healthy Japanese and Chinese participants |
| Name | Type | Description |
|---|---|---|
| LY4298445 | DRUG | Administered SC |
Inclusion Criteria: Healthy Participants Healthy participants between the ages of 18 and 55 years. * Have body weight of at least 50 kilograms (kg) and body mass index (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive. Participants with Systemic Lupus Erythematosus (SLE) * Are...